Literature DB >> 19168790

ETS2 and ERG promote megakaryopoiesis and synergize with alterations in GATA-1 to immortalize hematopoietic progenitor cells.

Monika J Stankiewicz1, John D Crispino.   

Abstract

ETS2 and ERG are transcription factors, encoded on human chromosome 21 (Hsa21), that have been implicated in human cancer. People with Down syndrome (DS), who are trisomic for Hsa21, are predisposed to acute megakaryoblastic leukemia (AMKL). DS-AMKL blasts harbor a mutation in GATA1, which leads to loss of full-length protein but expression of the GATA-1s isoform. To assess the consequences of ETS protein misexpression on megakaryopoiesis, we expressed ETS2, ERG, and the related protein FLI-1 in wild-type and Gata1 mutant murine fetal liver progenitors. These studies revealed that ETS2, ERG, and FLI-1 facilitated the expansion of megakaryocytes from wild-type, Gata1-knockdown, and Gata1s knockin progenitors, but none of the genes could overcome the differentiation block characteristic of the Gata1-knockdown megakaryocytes. Although overexpression of ETS proteins increased the proportion of CD41(+) cells generated from Gata1s-knockin progenitors, their expression led to a significant reduction in the more mature CD42 fraction. Serial replating assays revealed that overexpression of ERG or FLI-1 immortalized Gata1-knockdown and Gata1s knockin, but not wild-type, fetal liver progenitors. Immortalization was accompanied by activation of the JAK/STAT pathway, commonly seen in megakaryocytic malignancies. These findings provide evidence for synergy between alterations in GATA-1 and overexpression of ETS proteins in aberrant megakaryopoiesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168790      PMCID: PMC2665899          DOI: 10.1182/blood-2008-08-174813

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1.

Authors:  Melissa L Holmes; Natalie Bartle; Michael Eisbacher; Beng H Chong
Journal:  J Biol Chem       Date:  2002-09-30       Impact factor: 5.157

Review 2.  Transient leukaemia--a benign form of leukaemia in newborn infants with trisomy 21.

Authors:  Alvin Zipursky
Journal:  Br J Haematol       Date:  2003-03       Impact factor: 6.998

3.  Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.

Authors:  E Ito; M Kasai; Y Hayashi; T Toki; K Arai; S Yokoyama; K Kato; N Tachibana; M Yamamoto; M Yokoyama
Journal:  Br J Haematol       Date:  1995-07       Impact factor: 6.998

4.  Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.

Authors:  Yubin Ge; Alan A Dombkowski; Katherine M LaFiura; Dana Tatman; Ravikiran S Yedidi; Mark L Stout; Steven A Buck; Gita Massey; David L Becton; Howard J Weinstein; Yaddanapudi Ravindranath; Larry H Matherly; Jeffrey W Taub
Journal:  Blood       Date:  2005-10-25       Impact factor: 22.113

5.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 6.  Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome.

Authors:  Sandeep Gurbuxani; Paresh Vyas; John D Crispino
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

7.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy.

Authors:  Y Ge; K M LaFiura; A A Dombkowski; Q Chen; S G Payton; S A Buck; S Salagrama; A E Diakiw; L H Matherly; J W Taub
Journal:  Leukemia       Date:  2007-12-20       Impact factor: 11.528

9.  Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.

Authors:  Gina Kirsammer; Sarah Jilani; Hui Liu; Elizabeth Davis; Sandeep Gurbuxani; Michelle M Le Beau; John D Crispino
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

10.  nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays.

Authors:  Pan Du; Warren A Kibbe; Simon M Lin
Journal:  Biol Direct       Date:  2007-05-31       Impact factor: 4.540

View more
  45 in total

1.  Thrombocytopenia in mice lacking the carboxy-terminal regulatory domain of the Ets transcription factor Fli1.

Authors:  Omar Moussa; Amanda C LaRue; Romeo S Abangan; Christopher R Williams; Xian K Zhang; Masahiro Masuya; Yong Z Gong; Demetri D Spyropoulos; Makio Ogawa; Gary Gilkeson; Dennis K Watson
Journal:  Mol Cell Biol       Date:  2010-09-07       Impact factor: 4.272

Review 2.  Normal and malignant megakaryopoiesis.

Authors:  Qiang Wen; Benjamin Goldenson; John D Crispino
Journal:  Expert Rev Mol Med       Date:  2011-10-21       Impact factor: 5.600

3.  The ERGonomics of hematopoietic stem cell self-renewal.

Authors:  Scott A Lacadie; Leonard I Zon
Journal:  Genes Dev       Date:  2011-02-15       Impact factor: 11.361

4.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

Review 5.  Cohesin Mutations in Myeloid Malignancies.

Authors:  Joseph B Fisher; Maureen McNulty; Michael J Burke; John D Crispino; Sridhar Rao
Journal:  Trends Cancer       Date:  2017-04

Review 6.  The oncogenic role of the ETS transcription factors MEF and ERG.

Authors:  Goro Sashida; Elena Bazzoli; Silvia Menendez; Yan Liu; Stephen D Nimer
Journal:  Cell Cycle       Date:  2010-09-13       Impact factor: 4.534

Review 7.  Mouse models of diseases of megakaryocyte and platelet homeostasis.

Authors:  Catherine L Carmichael; Warren S Alexander
Journal:  Mamm Genome       Date:  2011-06-11       Impact factor: 2.957

8.  Hematopoietic overexpression of the transcription factor Erg induces lymphoid and erythro-megakaryocytic leukemia.

Authors:  Catherine L Carmichael; Donald Metcalf; Katya J Henley; Elizabeth A Kruse; Ladina Di Rago; Sandra Mifsud; Warren S Alexander; Benjamin T Kile
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-30       Impact factor: 11.205

9.  Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.

Authors:  Yehudit Birger; Liat Goldberg; Timothy M Chlon; Benjamin Goldenson; Inna Muler; Ginette Schiby; Jasmin Jacob-Hirsch; Gideon Rechavi; John D Crispino; Shai Izraeli
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

10.  Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction.

Authors:  John D Eicher; Yoshiyuki Wakabayashi; Olga Vitseva; Nada Esa; Yanqin Yang; Jun Zhu; Jane E Freedman; David D McManus; Andrew D Johnson
Journal:  Platelets       Date:  2015-09-14       Impact factor: 3.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.